Home>
US Stocks>
Biocryst Pharmaceuticals

Biocryst Pharmaceuticals share price today

(BCRX)

Biocryst Pharmaceuticals share price is $7.67 & ₹653.47 as on 25 Dec 2024, 2.30 'hrs' IST

$7.67

▲

-0.11

(-1.41%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Biocryst Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Biocryst Pharmaceuticals from India. Also see the sentimental analysis on Indian investors investing in Biocryst Pharmaceuticals. Get details on the Indian mutual funds that are investing in Biocryst Pharmaceuticals. Get Analyst recommendations and forecasts along with all the Biocryst Pharmaceuticals's financials.

Biocryst Pharmaceuticals share price movements

Today's Low: $7.61
Today's High: $7.83
$7.67
0.78%
Downside
Day's Volatility :2.75%
Upside
1.98%
52 Weeks Low: $4.03
52 Weeks High: $8.88
$7.67
47.46%
Downside
52 Weeks Volatility :54.62%
Upside
13.63%

Biocryst Pharmaceuticals Returns

Period	Biocryst Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	1.19%	-9.0%	0.0%
6 Months	25.53%	-4.6%	0.0%
1 Year	23.91%	3.0%	0.0%
3 Years	-44.54%	0.0%	-21.1%

Biocryst Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$7.78
Open	$7.73
Today's High	$7.825
Today's Low	$7.61
Market Capitalization	$1.6B
Today's Volume	$751.8K
52 Week High	$8.88
52 Week Low	$4.03
Revenue TTM	$412.6M
EBITDA	$-31.9M
Earnings Per Share (EPS)	$-0.61
Profit Margin	-30.01%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1925.37%

How to invest in Biocryst Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Biocryst Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biocryst Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Biocryst Pharmaceuticals or BCRX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biocryst Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biocryst Pharmaceuticals shares which would translate to 0.111 fractional shares of Biocryst Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Biocryst Pharmaceuticals, in just a few clicks!

Returns in Biocryst Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

Biocryst Pharmaceuticals investment value today

Current value as on today

₹1,26,148

Returns

₹26,148

(+26.15%)

Returns from Biocryst Pharmaceuticals Stock

₹23,910 (+23.91%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Biocryst Pharmaceuticals

50%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Biocryst Pharmaceuticals on INDmoney from India has grown in the last 30 days as on Dec 26, 2024. 50% more investors are searching Biocryst Pharmaceuticals in the last 30 days versus the previous period.

Global Institutional Holdings in Biocryst Pharmaceuticals

Vanguard Group Inc
9.80%
BlackRock Inc
9.63%
venBio Select Advisor LLC
5.73%
Kynam Capital Management, LP
4.39%
State Street Corp
4.27%
Deerfield Management Co
3.93%

Analyst Recommendation on Biocryst Pharmaceuticals

Buy

83%Buy

16%Hold

0%Sell

Based on 18 Wall street analysts offering stock ratings for Biocryst Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 18 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Biocryst Pharmaceuticals

What analysts predicted

Upside of 93.2%

Current:

$7.67

Target:

$14.82

Insights on Biocryst Pharmaceuticals

Price Movement
In the last 7 days, BCRX stock has moved up by 3.8%
Increasing Revenue
Revenue is up for the last 3 quarters, 92.76M → 117.08M (in $), with an average increase of 10.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -12.67M → -14.03M (in $), with an average decrease of 10.7% per quarter
BCRX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 27.2% return, outperforming this stock by 1.0%
BCRX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 25.2% return, outperforming this stock by 70.1%
Price to Sales
ForBCRX every $1 of sales, investors are willing to pay $3.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.7 for every $1 of sales.

Biocryst Pharmaceuticals Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$20.7M	↓ 18.0%
Net Income	$-101.3M	↑ 53.92%
Net Profit Margin	-490.25%	↓ 229.07%

	FY19	Y/Y Change
Revenue	$48.8M	↑ 136.45%
Net Income	$-120.1M	↑ 18.58%
Net Profit Margin	-245.86%	↑ 244.39%

	FY20	Y/Y Change
Revenue	$17.8M	↓ 63.53%
Net Income	$-196.6M	↑ 63.72%
Net Profit Margin	-1.1K%	↓ 857.71%

	FY21	Y/Y Change
Revenue	$157.2M	↑ 782.38%
Net Income	$-184.1M	↓ 6.36%
Net Profit Margin	-117.11%	↑ 986.46%

	FY22	Y/Y Change
Revenue	$270.8M	↑ 72.31%
Net Income	$-247.1M	↑ 34.26%
Net Profit Margin	-91.25%	↑ 25.86%

	FY23	Y/Y Change
Revenue	$331.4M	↑ 22.37%
Net Income	$-226.5M	↓ 8.33%
Net Profit Margin	-68.36%	↑ 22.89%

	Q2 FY23	Q/Q Change
Revenue	$82.5M	↑ 19.94%
Net Income	$-75.3M	↑ 41.24%
Net Profit Margin	-91.31%	↓ 13.77%

	Q3 FY23	Q/Q Change
Revenue	$86.7M	↑ 5.15%
Net Income	$-36.1M	↓ 52.01%
Net Profit Margin	-41.67%	↑ 49.64%

	Q4 FY23	Q/Q Change
Revenue	$93.4M	↑ 7.68%
Net Income	$-61.7M	↑ 70.77%
Net Profit Margin	-66.09%	↓ 24.42%

	Q1 FY24	Q/Q Change
Revenue	$92.8M	↓ 0.69%
Net Income	$-35.4M	↓ 42.69%
Net Profit Margin	-38.14%	↑ 27.95%

	Q2 FY24	Q/Q Change
Revenue	$109.3M	↑ 17.86%
Net Income	$-12.7M	↓ 64.18%
Net Profit Margin	-11.59%	↑ 26.55%

	Q3 FY24	Q/Q Change
Revenue	$117.1M	↑ 7.09%
Net Income	$-14.0M	↑ 10.72%
Net Profit Margin	-11.99%	↓ 0.4%

	FY18	Y/Y Change
Profit	$20.2M	↓ 14.06%

	FY19	Y/Y Change
Profit	$44.7M	↑ 121.65%

	FY20	Y/Y Change
Profit	$16.1M	↓ 63.93%

	FY21	Y/Y Change
Profit	$149.9M	↑ 829.02%

	FY22	Y/Y Change
Profit	$264.2M	↑ 76.27%

	FY23	Y/Y Change
Profit	$326.8M	↑ 23.66%

	Q2 FY23	Q/Q Change
Profit	$81.5M	↑ 20.2%

	Q3 FY23	Q/Q Change
Profit	$85.6M	↑ 4.99%

	Q4 FY23	Q/Q Change
Profit	$91.3M	↑ 6.7%

	Q1 FY24	Q/Q Change
Profit	$91.5M	↑ 0.17%

	Q2 FY24	Q/Q Change
Profit	$107.3M	↑ 17.25%

	Q3 FY24	Q/Q Change
Profit	$113.9M	↑ 6.13%

	FY18	Y/Y Change
Operating Cash Flow	$-92.6M	↑ 124.98%
Investing Cash Flow	$4.8M	↓ 107.18%
Financing Cash Flow	$62.5M	↓ 53.94%

	FY19	Y/Y Change
Operating Cash Flow	$-89.6M	↓ 3.22%
Investing Cash Flow	$77.9M	↑ 1534.52%
Financing Cash Flow	$99.1M	↑ 58.55%

	FY20	Y/Y Change
Operating Cash Flow	$-137.2M	↑ 53.17%
Investing Cash Flow	$-6.9M	↓ 108.8%
Financing Cash Flow	$302.7M	↑ 205.45%

	FY21	Y/Y Change
Operating Cash Flow	$-142.2M	↑ 3.6%
Investing Cash Flow	$15.8M	↓ 330.51%
Financing Cash Flow	$359.7M	↑ 18.82%

	FY22	Y/Y Change
Operating Cash Flow	$-161.9M	↑ 13.85%
Investing Cash Flow	$-128.2M	↓ 911.43%
Financing Cash Flow	$88.0M	↓ 75.53%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-18.8M	↓ 60.4%
Investing Cash Flow	$-19.0M	↓ 82.23%
Financing Cash Flow	$29.4M	↑ 478.22%

Biocryst Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Biocryst Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Biocryst Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biocryst Pharmaceuticals Inc	2.4%	25.53%	23.91%	-44.54%	138.2%
Regeneron Pharmaceuticals, Inc.	-5.12%	-32.01%	-18.29%	12.56%	91.19%
Biontech Se	-3.72%	41.99%	6.11%	-55.22%	226.93%
Alnylam Pharmaceuticals, Inc.	-3.99%	-1.52%	23.75%	50.98%	112.09%
Vertex Pharmaceuticals Incorporated	-12.61%	-13.61%	0.03%	83.58%	86.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biocryst Pharmaceuticals Inc	NA	NA	-0.28	-0.36	-19.25	-0.04	NA	-2.26
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biocryst Pharmaceuticals Inc	Buy	$1.6B	138.2%	NA	-30.01%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	91.19%	17.67	33.61%
Biontech Se	Buy	$27.4B	226.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	112.09%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$105.1B	86.41%	32.84	-4.51%

About Biocryst Pharmaceuticals

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.

Organization	Biocryst Pharmaceuticals
Employees	536
CEO	Mr. Jon P. Stonehouse
Industry	Health Technology

Management People of Biocryst Pharmaceuticals

Name	Title
Mr. Jon P. Stonehouse	CEO, President & Executive Director
Mr. Anthony J. Doyle	Senior VP, CFO & Interim Principal Accounting Officer
Ms. Alane P. Barnes	Senior VP, Chief Legal Officer & Corporate Secretary
Dr. Helen M. Thackray FAAP, M.D.	Chief Research & Development Officer
Mr. Charles K. Gayer	Senior VP & Chief Commercial Officer
Mr. John D. Bluth	Chief Communications Officer
Ms. Stephanie Angelini	Chief People Officer
Dr. William P. Sheridan MBBS	Chief Development Officer
Dr. Yarlagadda S. Babu Ph.D.	Chief Discovery Officer
Ms. Jinky Ang Rosselli	Chief Data & Insights Officer

Important FAQs about investing in Biocryst Pharmaceuticals from India :

What is Biocryst Pharmaceuticals share price today?

Biocryst Pharmaceuticals share price today stands at $7.67, Open: $7.73 ; Previous Close: $7.78 ; High: $7.83 ; Low: $7.61 ; 52 Week High: $8.88 ; 52 Week Low: $4.03. The stock opens at $7.73, after a previous close of $7.78. The stock reached a daily high of $7.83 and a low of $7.61, with a 52-week high of $8.88 and a 52-week low of $4.03.

Can Indians buy Biocryst Pharmaceuticals shares?

Yes, Indians can invest in the Biocryst Pharmaceuticals (BCRX) from India.

With INDmoney, you can buy Biocryst Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biocryst Pharmaceuticals at zero transaction cost.

How can I buy Biocryst Pharmaceuticals shares from India?

It is very easy to buy Biocryst Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biocryst Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Biocryst Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Biocryst Pharmaceuticals stocks?

To start investing in Biocryst Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.